Nodding Syndrome Associated with Onchocerciasis
Neuroepidemiology · 2024
DOI: 10.1159/000538223 ↗Kurz gefasst
Leserbrief in der Zeitschrift Neuroepidemiology, 2024. Verfasst von Robert Colebunders und 1 weiteren Autor:innen. Beteiligte Einrichtung: Global Health Institute, University of Antwerp, Antwerp, Belgium. Hauptthemen laut MEDLINE: Onchocerciasis, Nodding Syndrome. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 12 Literaturangaben.
Abstract (Originalsprache)
We read with interest the systematic review by Metanmo et al. [1] which elaborated on the different potential causal factors of nodding syndrome (NS) that have been investigated in the past. Their meta-analytic fi ndings highlighted onchocerciasis as a main factor associated with NS (OR = 8.8 [4.8, 15.9]) [1]. However, the authors remained critical about the potential role of onchocerciasis in causing NS. However, they omitted important studies that demonstrated a decreasing NS incidence following the implementation of ef fi cient onchocerciasis elimination measures (Table 1). Some points that emerged from the authors ’ synthesis of literature need to be addressed to further clarify our understanding of NS and how it relates to onchocerciasis:
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Autor:innen und Institutionen
- Global Health Institute, University of Antwerp, Antwerp, Belgium.
- Department of Tropical Biology, Liverpool School of Tropical Medicine, Liverpool, UK.
- Brain Research Africa Initiative (BRAIN), Yaoundé, Cameroon.
Zitieren
APA
Colebunders, R., & Siewe Fodjo, J. N. (2024). Nodding Syndrome Associated with Onchocerciasis. Neuroepidemiology. https://doi.org/10.1159/000538223
Vancouver
Colebunders R, Siewe Fodjo JN. Nodding Syndrome Associated with Onchocerciasis. Neuroepidemiology. 2024. doi:10.1159/000538223
BibTeX
@article{Colebunders2024,
author = {Colebunders, Robert and Siewe Fodjo, Joseph Nelson},
title = {Nodding Syndrome Associated with Onchocerciasis},
journal = {Neuroepidemiology},
year = {2024},
doi = {10.1159/000538223}
}
EUVIMED